Cargando…

Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)‐TIMI 50

BACKGROUND: Our dual aims were as follows: (1) to classify new or recurrent myocardial infarctions (MI) in patients with stable atherosclerosis using the Universal Definition of MI classification system; and (2) to characterize the effects of vorapaxar, a first‐in‐class platelet protease‐activated r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kidd, Stephen K., Bonaca, Marc P., Braunwald, Eugene, De Ferrari, Gaetano M., Lewis, Basil S., Merlini, Piera A., Murphy, Sabina A., Scirica, Benjamin M., White, Harvey D., Morrow, David A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015369/ https://www.ncbi.nlm.nih.gov/pubmed/27431644 http://dx.doi.org/10.1161/JAHA.116.003237

Ejemplares similares

Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial
por: Cavender, Matthew A., et al.
Publicado: (2015)

Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2°P‐TIMI 50 trial
por: Freedman, Benjamin L., et al.
Publicado: (2022)

Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P‐TIMI 50
por: Berg, David D., et al.
Publicado: (2021)

Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease
por: Bergmark, Brian A., et al.
Publicado: (2018)

Response to Mei et al. regarding the incidence and predictors of hospitalization for heart failure among patients with stable atherosclerosis in the TRA 2°P‐TIMI 50 trial
por: Freedman, Benjamin L., et al.
Publicado: (2023)

Efficacy and Safety of Vorapaxar by Intensity of Background Lipid‐Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P‐TIMI 50 Trial
por: Gilchrist, Ian C., et al.
Publicado: (2021)

Dynamic TIMI Risk Score for STEMI
por: Amin, Sameer T., et al.
Publicado: (2013)

Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial
por: Zelniker, Thomas A., et al.
Publicado: (2021)

Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes
por: Røysland, Ragnhild, et al.
Publicado: (2012)

Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54
por: Bonaca, Marc P., et al.
Publicado: (2018)

Plasma Omega‐3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN‐TIMI 36
por: Zelniker, Thomas A., et al.
Publicado: (2021)

Long‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial
por: Bergmark, Brian A., et al.
Publicado: (2021)

Novel Therapeutic Approaches to Prevent Atherothrombotic Ischemic Stroke in Patients with Carotid Atherosclerosis
por: Puig, Núria, et al.
Publicado: (2023)

Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial
por: Kato, Eri Toda, et al.
Publicado: (2016)

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial
por: Murphy, Sabina A., et al.
Publicado: (2008)

Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF‐TIMI 48 Trial
por: Fanola, Christina L., et al.
Publicado: (2018)

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
por: Magnani, Giulia, et al.
Publicado: (2015)

Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI48 Trial
por: Xu, Haiyan, et al.
Publicado: (2016)

Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF‐TIMI 48 Trial
por: Eisen, Alon, et al.
Publicado: (2017)

Safety and Efficacy of Rivaroxaban When Added to Aspirin Monotherapy Among Stabilized Post‐Acute Coronary Syndrome Patients: A Pooled Analysis Study of ATLAS ACS‐TIMI 46 and ATLAS ACS 2‐TIMI 51
por: Gibson, William J., et al.
Publicado: (2019)

Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54
por: Dellborg, Mikael, et al.
Publicado: (2019)

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer
por: Yuan, Kaiyu, et al.
Publicado: (2015)

HEART and TIMI Scores Predict Severe Coronary Atherosclerosis in Patients With End-Stage Renal Disease
por: Parikh, Trishna B, et al.
Publicado: (2023)

Antiplatelet combinations for prevention of atherothrombotic events
por: Bollati, Mario, et al.
Publicado: (2011)

Novel Antiplatelet Therapies for Atherothrombotic Diseases
por: Majithia, Arjun, et al.
Publicado: (2019)

Hematopoiesis of Indeterminate Potential and Atherothrombotic Risk
por: Murphy, Andrew J., et al.
Publicado: (2022)

Unexplored Roles of Erythrocytes in Atherothrombotic Stroke
por: Papadopoulos, Charalampos, et al.
Publicado: (2023)

PCSK9 as an Atherothrombotic Risk Factor
por: Sotler, Tadeja, et al.
Publicado: (2023)

Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial)
por: Aoki, Yasunori, et al.
Publicado: (2021)

SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins
por: Singh, Awadhesh K., et al.
Publicado: (2019)

Interleukin‐6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID‐TIMI 52 (Stabilization of Plaque Using Darapladib—Thrombolysis in Myocardial Infarction 52) Trial
por: Fanola, Christina L., et al.
Publicado: (2017)

Increased serum alkaline phosphatase and early neurological deterioration in patients with atherothrombotic brain infarction attributable to intracranial atherosclerosis
por: Uehara, Toshiyuki, et al.
Publicado: (2020)

Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF‐TIMI 48 Trial
por: Eisen, Alon, et al.
Publicado: (2016)

Environmental noise exposure is associated with atherothrombotic risk
por: Koczorowski, Magali, et al.
Publicado: (2022)

Role of Oxidative Stress in the Pathogenesis of Atherothrombotic Diseases
por: Petrucci, Giovanna, et al.
Publicado: (2022)

Gut Microbiota‐Dependent Trimethylamine N‐oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS‐TIMI 54 Trial
por: Gencer, Baris, et al.
Publicado: (2020)

Biomarker of Collagen Turnover (C‐Terminal Telopeptide) and Prognosis in Patients With Non‐ST‐Elevation Acute Coronary Syndromes
por: Zelniker, Thomas A., et al.
Publicado: (2019)

Importance of the TIMI frame count: implications for future trials
por: Appleby, Mark A, et al.
Publicado: (2000)

TIMI perfusion grade compared to TIMI flow in prediction of infarct size and microvascular obstruction measured by contrast-enhanced MRI
por: Fuernau, Georg FK, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_qmrugif8re6esu05ufjm5udi93